Spots Global Cancer Trial Database for myeloproliferative neoplasms
Every month we try and update this database with for myeloproliferative neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms | NCT02823184 | Polycythemia Ve... Essential Throm... | RNA sample of t... | 18 Years - | University Hospital, Bordeaux | |
| Safety Evaluation Study for Patients With Polycythemia Vera | NCT05074550 | Polycythemia Ve... | PPMX-T003 | 20 Years - 75 Years | Perseus Proteomics Inc. | |
| Registry of Patients With MPNs in Taiwan | NCT03618485 | Myeloproliferat... | 20 Years - | Chang Gung Memorial Hospital | ||
| To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) | NCT04629508 | Myelofibrosis Polycythemia Ve... Thrombocythemia | itacitinib | 18 Years - | Incyte Corporation | |
| Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | NCT04285086 | Essential Throm... | Ropeginterferon... Anagrelide | 18 Years - | PharmaEssentia | |
| Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients | NCT01340651 | Myelofibrosis | Ruxolitinib | 18 Years - | Incyte Corporation | |
| Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr) | NCT05419648 | Myeloproliferat... | 1 additional tu... | 18 Years - | University Hospital, Bordeaux | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms | NCT05444530 | Myeloproliferat... | VAC85135 Ipilimumab | 18 Years - | Janssen Research & Development, LLC | |
| A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms | NCT03075826 | Myeloproliferat... | SGI-110 | 18 Years - | Weill Medical College of Cornell University | |
| Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome | NCT02269592 | Monoclonal Gamm... Chronic Lymphoc... Myelodysplastic... Hematological M... B-cell Malignan... Myelodysplastic... IgG Monoclonal ... Smoldering Mult... Waldenstrom Mac... | 18 Years - | Dana-Farber Cancer Institute | ||
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | NCT05936359 | Myeloproliferat... | INCA033989 Ruxolitinib | 18 Years - | Incyte Corporation | |
| Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | NCT04285086 | Essential Throm... | Ropeginterferon... Anagrelide | 18 Years - | PharmaEssentia | |
| Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK) | NCT05839717 | Myeloproliferat... | Blood sampling | 18 Years - | University Hospital, Bordeaux | |
| Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) | NCT02410551 | Myeloproliferat... | Pacritinib Busulfan Questionnaires Phone Calls Allogeneic Stem... Fludarabine | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Risk Factors and Predictors of Thrombosis in Myeloprolferative Neoplasms | NCT03599700 | Thrombosis | myeloproliferat... | 18 Years - | Assiut University | |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | NCT03314974 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M... | HSCT with TBI R... HSCT with Non-T... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders | NCT02823210 | Myeloproliferat... | - | Assistance Publique - Hôpitaux de Paris | ||
| Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF | NCT01423851 | Primary Myelofi... Post-Polycythem... Post-Essential ... | NS-018 | 18 Years - | NS Pharma, Inc. | |
| Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. | NCT04866056 | Myelodysplastic... Myeloproliferat... Myelofibrosis | Jaktinib azacitidine | 18 Years - | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment | NCT04576156 | Myelofibrosis | Imetelstat Best Available ... | 18 Years - | Geron Corporation | |
| A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET | NCT05482971 | Essential Throm... | Ropeginterferon... | 18 Years - | PharmaEssentia | |
| Safety Evaluation Study for Patients With Polycythemia Vera | NCT05074550 | Polycythemia Ve... | PPMX-T003 | 20 Years - 75 Years | Perseus Proteomics Inc. | |
| Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients | NCT04655092 | Polycythemia Ve... | P1101 (Ropegint... | 20 Years - | PharmaEssentia Japan K.K. | |
| To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | NCT04551066 | Myelofibrosis Primary Myelofi... Post Essential ... Post Polycythem... | parsaclisib ruxolitinib placebo | 18 Years - | Incyte Corporation | |
| Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of MNP Ph1- | NCT02862366 | Myeloproliferat... | Blood sampling | 18 Years - | Lille Catholic University | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene | |
| A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | NCT03912064 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Myelofibrosis | Ipilimumab CD25hi Treg dep... | 18 Years - | Dana-Farber Cancer Institute | |
| Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation | NCT06291987 | Myeloproliferat... | Ivosidenib Ruxolitinib | 18 Years - | University of Chicago | |
| Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) | NCT03745378 | Polycythemia Ve... Essential Throm... Myelofibrosis | JAK2V617F mutat... | - | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | |
| Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | NCT04562389 | Myelofibrosis | Selinexor Selinexor Placebo Ruxolitinib | 18 Years - | Karyopharm Therapeutics Inc | |
| Registry of Patients With MPNs in Taiwan | NCT03618485 | Myeloproliferat... | 20 Years - | Chang Gung Memorial Hospital | ||
| Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML | NCT02076191 | Myeloproliferat... | Ruxolitinib Decitabine | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms | NCT05444530 | Myeloproliferat... | VAC85135 Ipilimumab | 18 Years - | Janssen Research & Development, LLC | |
| Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply | NCT04182100 | Polycythemia Ve... | P1101 Low-dose aspiri... Phlebotomy | 20 Years - | PharmaEssentia Japan K.K. | |
| Study of Select Combinations in Adults With Myelofibrosis | NCT04283526 | Primary Myelofi... Myelofibrosis PMF Post-Essential ... Post-Polycythem... | MBG453 NIS793 Spartalizumab Decitabine | 18 Years - | Novartis | |
| A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms | NCT04339400 | Myeloproliferat... | TQ05105 | 18 Years - | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | NCT03386513 | Blastic Plasmac... Myeloproliferat... | IMGN632 | 18 Years - | ImmunoGen, Inc. | |
| A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | NCT06313593 | Myeloproliferat... | INCB160058 | 18 Years - | Incyte Corporation | |
| Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation | NCT06291987 | Myeloproliferat... | Ivosidenib Ruxolitinib | 18 Years - | University of Chicago | |
| Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | NCT04562389 | Myelofibrosis | Selinexor Selinexor Placebo Ruxolitinib | 18 Years - | Karyopharm Therapeutics Inc | |
| Aquagenic Pruritus in Myeloproliferative Neoplasms | NCT04018209 | Deciphering Aqu... | 18 Years - | University Hospital, Brest | ||
| Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation | NCT06291987 | Myeloproliferat... | Ivosidenib Ruxolitinib | 18 Years - | University of Chicago | |
| A Study to Evaluate P1101 in Japanese PV Patients | NCT06002490 | Polycythemia Ve... | P1101 Low-dose aspiri... Phlebotomy | 18 Years - | PharmaEssentia Japan K.K. | |
| HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET | NCT01668173 | Myeloproliferat... | AUY922 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | NCT02393248 | Lung Cancer Solid Tumor Gastric Cancer Urothelial Canc... Endometrial Can... Multiple Myelom... Myeloproliferat... Breast Cancer Cholangiocarcin... UC MPN | Pemigatinib Gemcitabine Pembrolizumab Docetaxel Trastuzumab Retifanlimab Cisplatin | 18 Years - | Incyte Corporation | |
| CO-Rebreathing in Comparison to Isotopic Red Cell Volume Determination in the Diagnosis of Primitive and Secondary Polycythemia | NCT03008642 | Polycythemia | CO-Rebreathing ... | 18 Years - 80 Years | Centre Hospitalier Universitaire, Amiens | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene | |
| Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF | NCT01423851 | Primary Myelofi... Post-Polycythem... Post-Essential ... | NS-018 | 18 Years - | NS Pharma, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
